AxoGen (NASDAQ: AXGN) and Arch Therapeutics (OTCMKTS:ARTH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for AxoGen and Arch Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AxoGen 0 0 6 0 3.00
Arch Therapeutics 0 0 4 0 3.00

AxoGen presently has a consensus target price of $26.17, indicating a potential downside of 1.07%. Arch Therapeutics has a consensus target price of $2.83, indicating a potential upside of 289.19%. Given Arch Therapeutics’ higher probable upside, analysts clearly believe Arch Therapeutics is more favorable than AxoGen.

Profitability

This table compares AxoGen and Arch Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AxoGen -24.74% -91.00% -25.48%
Arch Therapeutics N/A -246.16% -130.60%

Institutional & Insider Ownership

66.0% of AxoGen shares are held by institutional investors. Comparatively, 0.0% of Arch Therapeutics shares are held by institutional investors. 9.3% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares AxoGen and Arch Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AxoGen $41.11 million 21.93 -$14.41 million ($0.40) -66.13
Arch Therapeutics N/A N/A -$7.78 million ($0.04) -18.20

Arch Therapeutics has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Arch Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AxoGen has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Arch Therapeutics has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Summary

AxoGen beats Arch Therapeutics on 6 of the 11 factors compared between the two stocks.

AxoGen Company Profile

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc. is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s primary product candidates, collectively known as the AC5 Devices (AC5), are designed to achieve hemostasis in surgical procedures. The Company’s product candidates rely on its self-assembling peptide technology and are designed to achieve hemostasis in skin wounds, and minimally invasive and open surgical procedures. The Company focuses on developing other product candidates based on its technology platform for use in a range of indications. As of September 30, 2016, the Company had not generated any revenues.

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.